Property:Results during intervention
This is a property of type Text.
B
Beer et al. (2007): Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators +
No significant differences in median duration of PSA progression-free survival;
median duration of tumor progression-free survival and median duration of clinical progression-free survival could not be reliably assessed due to the lack of regularly scheduled tumor imaging +
Beer et al. (2007): Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators +
No significant differences +
Beer et al. (2007): Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators +
The incidence of any grade 3 or 4 adverse events was not significantly different;
serious adverse events, generally those requiring hospitalization, were observed in 41% of placebo-treated patients and 27% of DN-101-treated patients (p = .023);
Among the grade 3 or 4 nonhematologic toxicities, the most common were fatigue (16% placebo; 8% DN-101), infection (13% placebo; 8% DN- 101), and hyperglycemia (12% placebo; 6% DN-101) +
Beer et al. (2007): Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators +
Within 6 months of enrollment: no significant differences in PSA decline;
at any time while on study: PSA decline achieved in 52% of placebo- treated patients and 63% of DN-101-treated patients (p = .07);
median time to PSA response was 5.3 months in placebo-treated patients and 2.9 months in DN-101-treated patients (p = .06) +
Bossi et al. (2017): A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin +
Incidence of delayed nausea: no significant differences overall
Cycle 1: (intervention vs. placebo: p=0.851
Cycle 2: intervention vs. placebo: p=0.379 Subgroup analysis : in the 2nd cycle lung cancer patients in intervention significantly higher than in placebo (OR 2.67 95%CI 1.03/6.87; p=0.042)
Significant delayed nausea: overall no significant differences Cycle 1: intervention vs. placebo: p=0.163
Cycle 2: intervention vs. placebo: p=0.239
Subgroup analysis: men in intervention significantly higher than in placebo (OR 2.74 95% CI 1.28/5.85; p<0.05) +
Bossi et al. (2017): A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin +
Incidence of anticipatory nausea: no significant differences Cycle 1: intervention vs. placebo: p=0.823
Cycle 2:intervention vs. placebo: p=0.629
Significant anticipatory nausea: no significant differences Cycle 1: intervention vs. placebo: p=0.666
Cycle 2: intervention vs. placebo: p=0.536 +
Bossi et al. (2017): A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin +
NA +
Bossi et al. (2017): A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin +
NA +
Bossi et al. (2017): A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin +
No significant difference between arms.
At cycle 1: worsening of the BFI score was smaller with ginger than placebo (treatment difference -0.23, 95% CI: -0.97 to 0.51).
At cycle 2: the situation was different: worsening with ginger was slightly higher than with placebo (treatment difference 0.09, 95% CI –0.71 to 0.89). During both cycles, differences in BFI scores were negligible. +
Bossi et al. (2017): A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin +
Incidence of inter-cycle nausea: no significant differences overall
Cycle 1: intervention vs. placebo:p=0.367
Cycle 2: intervention vs. placebo: p=0.417
Subgroup analysis: overall and in the first cycle lung cancer patients in intervention higher than in placebo (OR 2.77 95% CI 1.16/6.64; OR 4.27 95% CI 1.60/11.37)
Significant
inter-cycle nausea: no significant differences overall
Cycle 1: intervention vs. placebo: p=0.074
Cycle 2: intervention vs. placebo: p=0.361
Subgroup analysis:
Men significantly higher in intervention than in placebo (OR 2.38 95% CI 1.04/5.44; p<0.05) +
Braga et al. (2015): Effect of Zinc Supplementation on Serological Response to Vaccination Against Streptococcus Pneumoniae in Patients Undergoing Chemotherapy for Colorectal Cancer +
Zinc supplementation increased the zinc plasma concentrations +
Braga et al. (2015): Effect of Zinc Supplementation on Serological Response to Vaccination Against Streptococcus Pneumoniae in Patients Undergoing Chemotherapy for Colorectal Cancer +
No significant difference in the rate of seroconversion against vaccine antigens according to selected antigens (PS1, PS5, PS6, PS9, PS14, PS18) +
Braga et al. (2015): Effect of Zinc Supplementation on Serological Response to Vaccination Against Streptococcus Pneumoniae in Patients Undergoing Chemotherapy for Colorectal Cancer +
Significantly higher prevaccinal concentrations of antibodies against polysaccharides PS1, PS5, PS6, PS9, PS14, and PS18 in both arms at both 4 and 16 week after vaccination;
concentrations of PS6-specific antibodies in the end of study significantly higher in the placebo arm (MW (95% CI): 2.96 (1.74–5.03), p < 0.01) +
Braik et al. (2014): Randomized trial of vitamin B6 for preventing hand-foot syndrome from capecitabine chemotherapy +
NI +
Braik et al. (2014): Randomized trial of vitamin B6 for preventing hand-foot syndrome from capecitabine chemotherapy +
NI +
Brown et al. (2019): Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Body Composition among Patients with Advanced or Metastatic Colorectal Cancer: A Randomized Trial +
NA +
Brown et al. (2019): Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Body Composition among Patients with Advanced or Metastatic Colorectal Cancer: A Randomized Trial +
Change in plasma 25(OH)D concentration from baseline to cycle 8 was not significantly associated with change in body weight, body mass index, muscle area, muscle attenuation, visceral adipose tissue area and subcutaneous adipose tissue area +
Brown et al. (2019): Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Body Composition among Patients with Advanced or Metastatic Colorectal Cancer: A Randomized Trial +
No significant differences +
Büntzel et al. (2010): Limited effects of selenium in the prevention of radiation-associated toxicities - results of a randomized study in head neck cancer patients +
Maximum toxicity intervention vs. control arm: dysphagia 22.7% vs. 35.3%, ageusia 22.7% vs. 47.1%, xerostomia 22.7% vs. 23.5%, and stomatitis 36.4% vs. 23.5%; no significant differences;
Significant mean difference between arms only for dysphagia at week 7: mean intervention arm 1.533 vs. control 2.167 (p=0.05) +
Büntzel et al. (2010): Selenium Substitution During Radiotherapy of Solid Tumours - Laboratory Data from Two Observation Studies in Gynaecological and Head and Neck Cancer Patients +
At baseline no significant differences;
Significant differences in selenium concentrations (serum and blood) at half of radiotherapy (p<0.0001) +